+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer



FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer



Pancreatology 2019



The analysis was conducted to assess the effect of front-line combination chemotherapies on progression free survival (PFS). The analysis was restricted to phase III randomized controlled trials (RCTs) in first-line therapy for advanced pancreatic cancer. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) was applied to the above phase III RCTs. We have also calculated differences in PFS between the different arms of each trial and the pharmacological costs necessary to get the benefit in PFS, for each trial. Our study evaluated 11 phase III randomized controlled trials (RCTs), including 4572 patients. Combining the costs of therapy with the measure of efficacy represented by the PFS, we have obtained 74.12 € per month of PFS gained for 5-FU, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX), 90.14 per month of PFS gained for gemcitabine and oxaliplatin (GEMOX) and 4708.70 € per month of PFS gained for the combination of gemcitabine plus nab-pacliatxel against gemcitabine alone. Combining pharmacological costs with the measure of efficacy represented by PFS, FOLFIRINOX is a cost-effective first-line for advanced pancreatic cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446911

Download citation: RISBibTeXText

PMID: 30704852

DOI: 10.1016/j.pan.2019.01.014


Related references

Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clinical and Experimental Medicine 2018, 2018

Second-line treatment after disease progression following first-line chemotherapy with modified Folfirinox in advanced pancreatic cancer patients. European Journal of Cancer 51: S456-S457, 2015

P-180 * Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study. Annals of Oncology 26(Suppl 4): Iv52-Iv52, 2015

Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Nutrition and Cancer 2019: 1-8, 2019

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. ChemoTherapy 59(4): 273-279, 2014

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (folfirinox) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Pancreatology 13(4): S36-S37, 2013

Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease 49(6): 692-696, 2017

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine 96(19): E6769, 2017

Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Current Oncology 21(1): E41-E51, 2014

O2-015 * Second-Line Chemotherapy By Folfirinox With Unresectable Pancreatic Cancer (Phase I, Ii Study). Annals of Oncology 24(Suppl 9): ix46-ix47, 2013

Combination chemotherapy for advanced non small cell lung cancer nsclc effective but at what cost. Clinical & Investigative Medicine 11(4 Suppl.): C94, 1988

FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(12): 2360-2363, 2016

Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology 2018, 2018

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Communications 39(1): 26, 2019

Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. Journal of Gastrointestinal Oncology 6(5): 511-515, 2015